Targanta Therapeutics Presents In Vitro Data Highlighting Oritavancin’s Potent Activity Against Gram-Positive Pathogens
25 Octubre 2008 - 11:15AM
Business Wire
Targanta Therapeutics Corporation (NASDAQ: TARG) today announced
the presentation of studies detailing oritavancin�s superior in
vitro potency at the combined annual meetings of the Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the
Infectious Disease Society of America (IDSA), taking place in
Washington, DC. These presentations highlight oritavancin�s potent
activity against a variety of gram-positive bacteria, including
those strains either non-susceptible or resistant to currently
available agents. The preclinical research underscores
oritavancin�s potential to address the limitations of currently
marketed therapies for serious gram-positive infections. Throughout
the meeting, multiple posters and slide presentations will describe
oritavancin�s key attributes including: Superior In Vitro Potency
Several presentations of data will showcase oritavancin�s superior
in vitro potency across a broad range of susceptible,
non-susceptible, and resistant pathogens relative to currently
available antibiotic treatments including vancomycin, linezolid,
daptomycin and teicoplanin. Consistent Activity Against
Contemporary Strains, Globally Contemporary surveillance studies
show that oritavancin retains potency against a myriad of recent
isolates of gram-positive pathogens surveyed worldwide. Oritavancin
is highly active against recently isolated�staphylococcal,
enterococcal and streptococcal strains. The schedule of
presentations is as follows: DATE � TIME � Type � AUTHOR � TITLE
Saturday, October 25 � 12:15 p.m. � 1:15 p.m. � Poster � Badal �
Oritavancin: Comparative in-vitro Activity Against
Hospital-Acquired Enterococci from a Multi-center Surveillance �
The ORION Study (C1-145) � � 12:15 p.m. � 1:15 p.m. � Poster �
Draghi � In vitro Activity of Oritavancin Against Gram-positive
Organisms in Europe: A Comparative Study of Clinical Trial and
Surveillance Results (C1-144) � � 12:15 p.m. � 1:15 p.m. � Poster �
Fritsche � Activity of Oritavancin Tested Against Contemporary
Gram-positive Pathogens Submitted to a Global Surveillance Program
(2008) � � 12:15 p.m. � 1:15 p.m. � Poster � Pankuch � Activity of
Oritavancin Against 200 Vancomycin Susceptible and Non-Susceptible
MRSA by MIC Testing (C1-186) � � 12:15 p.m. � 1:15 p.m. � Poster �
Saravolatz � In vitro Activity of Oritavancin Against CA-MRSA, VISA
and Daptomycin-Non-Susceptible Staphylococcus aureus (DNSSA)
(C1-187) � � 12:15 p.m. � 1:15 p.m. � Poster � Vashisht � Activity
of Oritavancin Against S. aureus, S. epidermidis, Enterococcus spp.
and S. pneumoniae, Isolated from Canadian Hospitals: Results of
CANWARD 2007 (C1-146) � � 12:15 p.m. � 1:15 p.m. � Poster � Vaudaux
� Comparative Activity of Oritavancin Against Methicillin-Resistant
Staphylococcus aureus (MRSA) Bloodstream Isolates from Geneva
University Hospital (C1-143) Tuesday, October 28 � 10:45 a.m.�
11:00 a.m. � Slides � Belley � Oritavancin (ORI) Combinations with
Linezolid (LIN) and Nafcillin (NAF) are Synergistic against
Vancomycin (VAN)-Nonsusceptible Staphylococcus aureus (SA)
(C1-3720) � � 11:15 a.m. � 12:15 p.m. � Slides � McKay � Impact of
Human Serum Albumin (HSA) on Oritavancin (ORI) In vitro Activity
against Enterococci (C1-3835) About Oritavancin Oritavancin is a
novel semi-synthetic lipoglycopeptide antibiotic candidate with
potent bactericidal (killing) activity against a broad spectrum of
gram-positive bacteria. In its intravenous (IV) formulation, the
product candidate has been tested in over 2,400 individuals and has
completed two Phase 3 studies for the treatment of complicated skin
and skin structure infections (cSSSI) in which the primary
endpoints were met. Targanta submitted a New Drug Application (NDA)
to the U.S. Food and Drug Administration (FDA) in February 2008
seeking to commercialize oritavancin for the treatment of cSSSI;
the FDA accepted the NDA submission for standard review,
establishing an action date of December 8, 2008. Targanta�s
Marketing Authorization Application (MAA) for oritavancin was
accepted for review by the European Medicines Agency (EMEA) in June
2008. Targanta is also developing an oral version of oritavancin
for the possible treatment of Clostridium difficile. About Targanta
Therapeutics Targanta Therapeutics Corporation (Nasdaq: TARG) is a
biopharmaceutical company focused on developing and commercializing
innovative antibiotics to treat serious infections in the hospital
and other institutional settings. The Company�s pipeline includes
an intravenous version of oritavancin, a semi-synthetic
lipoglycopeptide antibiotic currently awaiting U.S. and EU
regulatory approval, and, a program to develop an oral version of
oritavancin for the treatment of Clostridium difficile. The Company
has operations in Cambridge, MA, Indianapolis, IN, and Montreal,
Qu�bec, Canada. For more information on Targanta, visit
www.targanta.com. Safe Harbor Statement This press release contains
�forward-looking statements� that are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These are statements that are predictive in nature, that
depend upon or refer to future events or conditions or that include
words such as �may,� "will," "expects," "projects," "anticipates,"
"estimates," "believes," "intends," "plans," "should," "seeks,"
�hope� and similar expressions. Such statements include
oritavancin�s potential to address the limitations of currently
marketed therapies for serious gram-positive infections.
Forward-looking statements involve known and unknown risks and
uncertainties that may cause actual future results to differ
materially from those projected or contemplated in the
forward-looking statements. Forward-looking statements may be
significantly impacted by certain risks and uncertainties described
in Targanta�s filings with the Securities and Exchange Commission.
The risks and uncertainties referred to above include, but are not
limited to, risks related to Targanta�s dependence on the success
of oritavancin; delays in obtaining or a failure to obtain
regulatory approval for Targanta�s product candidates; failure of
any approved product to achieve significant commercial acceptance
in the medical community or receive reimbursement by third-party
payors; unfavorable clinical trial results; failure to maintain and
protect Targanta�s intellectual property assets and to avoid
infringing the intellectual property rights of others; competition
from other pharmaceutical or biotechnology companies; Targanta�s
potential inability to initiate and complete pre-clinical studies
and clinical trials for its product candidates; the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results; and those other risks factors that are
described more fully in the Company�s filings with the Securities
and Exchange Commission. Targanta does not undertake any obligation
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date of this release.
Targanta Therapeutics Corp (MM) (NASDAQ:TARG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Targanta Therapeutics Corp (MM) (NASDAQ:TARG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Targanta Therapeutics Corp (MM) (NASDAQ): 0 recent articles
Más de Targanta Therapeutics Corporation Artículos de Noticias